PIRIBEDIL IN THE TREATMENT OF MILD AND MODERATE COGNITIVE IMPAIRMENTS

Download full text PDF
Issue: 
3
Year: 
2017

Professor V. Zakharov, MD; O. Milovanova; D. Grishina; A. Lokshina, Candidate of Medical Sciences; N. Vakhnina, Candidate of Medical Sciences I.M. Sechenov First Moscow State Medical University

Mild and moderate cognitive impairments (CIs) are observed in the early stages of cerebral diseases and widespread in clinical practice. Despite their nosological heterogeneity, there is a common neurochemical substrate of non-dementia CIs as neurotransmitter (dopaminergic, noradrenergic, other) deficiency in many cases. Although today there is no single approach to therapy for non-dementia CIs, the experience suggests the potential effectiveness of compensation for dopaminergic and noradrenergic deficiency. There are data on the use of the dopamine agonist and α-adrenoreceptor piribedil to treat mild and moderate CIs. This therapy was shown to significantly improve cognitive functions, primarily governing (planning and control) functions and memory. The significant efficiency of the treatment was determined even at the end of its second week.
Keywords: 
neurology
mild and moderate cognitive impairments
dopaminergic and noradrenergic deficiency
pronoran

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Jahno N.N. Kognitivnye rasstrojstva v nevrologicheskoj klinike // Nevrol. zhurn. –2006; 11 (Pril. 1): 4–12.
  2. Jahno N.N., Lokshina A.B., Zaharov V.V. Legkie i umerennye kognitivnye rasstrojstva pri distsirkuljatornoj entsefalopatii // Klin. gerontol. –2005; 11 (9): 38–9.
  3. Roberts R., Geda Y., Knopman D. et al. The Mayo clinic study of aging: design and sampling, participation, baseline measures and sample characteristics // Neuroepidemiology. – 2008; 30: 58–69.
  4. Plassman B., Langa K., Fisher G. et al. Prevalence of cognitive impairment without dementia in the United States // Ann. Neurol. Med. – 2008; 148 (6): 427–34.
  5. Zaharov V.V. Vserossijskaja programma issledovanij epidemiologii i terapii kognitivnyh rasstrojstv v pozhilom vozraste (PROMETEJ) // Nevrol. zhurn. – 2006; 11: 27–32.
  6. Farias S., Mungas D., Reed B. et al. Progression of mild cognitive impairment to dementia in clinic vs community based cohorts // Arch. Neurol. – 2009; 66 (9): 1151–7.
  7. Petersen R., Knopman D., Boeve B. et al. Mild cognitive impairment: 10 years later // Arch. Neurol. – 2009; 66 (12): 1447–55.
  8. Petersen R. Early diagnosis of Alzheimer’s disease: is MCI too late? // Curr. Alzheimer. Res. – 2009; 6 (4): 324–30.
  9. Mueller S., Weiner M., Thal L. et al. The Alzheimer’s disease neuroimaging initiative. In: Neuroimaging clinics of North America: Alzheimer’s disease: 100 years of progress. J. Petrella, P. Doraiswamy (eds) / Philadelphia: Elsevier Saunders, 2005; 869–77.
  10. Raschetti R., Albanese E., Vanacore N. et al. Cholinestarase ihibitors in MCI: a systematic review of randiomized trials // PLoS Med. – 2007; 4 (11): 338.
  11. Jahno N.N., Preobrazhenskaja I.S., Zaharov V.V. i dr. Effektivnost' memantina u patsientov s nedementnymi kognitivnymi rasstrojstvami. Rezul'taty mnogotsentrovogo klinicheskogo nabljudenija // Nevrol. zhurn. – 2010; 15 (2): 52–8.
  12. Bäckman L., Ginovart N., Dixon R. et al. Age-related cognitive deficits mediated by changes in the striatal dopamine system // Am. J. Psychiatry. – 2000; 157: 635–7.
  13. Volkow N., Wang G., Fowler J. et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging // Ann. Neurol. – 1998; 44 (1): 143–7.
  14. Aston-Jones G., Rajkowsky J., Cohen J. Role of locus coeruleus in attention and behavioral flexibility // Biol. Psychiatry. –1999; 46: 1309–20.
  15. Nagaraia D., Jayashree S. Randomised study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment // Am. J. Psychiatry. – 2001; 158 (9): 1517–9.
  16. Zaharov V.V., Lokshina A.B. Primenenie preparata pronoran (piribedil) pri legkih kognitivnyh rasstrojstvah u pozhilyh bol'nyh s distsirkuljatornoj entsefalopatiej // Nevrol. zhurn. – 2004; 2: 30–5.
  17. Jahno N.N., Zaharov V.V. Lechenie nedementnyh kognitivnyh narushenij u patsientov s arterial'noj gipertenziej i tserebral'nym aterosklerozom // Nevrol. zhurn. – 2012; 4: 49–55.
  18. Jahno N.N., Preobrazhenskaja I.S., Zaharov V.V. i dr. Rasprostranennost' kogpitivnyh narushenij pri nevrologicheskih zabolevanijah (analiz aboty spetsializirovannogo ambulatornogo priema) // Nevrol., nejropsihiat., psihosomat. – 2012; 2: 30–4.
  19. Jahno N.N., Levin O.S., Damulin I.V. Sopostavlenie klinicheskih i MRT-dannyh pri distsirkuljatornoj entsefalopatii. Soobschenie 2: kognitivnye narushenija // Nevrol. zhurn. – 2001; 6 (3): 10–9.
  20. Jahno N.N., Zaharov V.V., Lokshina A.B. i dr. Dementsii. Prakticheskoe rukovodstvo dlja vrachej / M.: MEDpress-inform, 2010; 272 s.
  21. DeKeyser J., Herregodts P., Ebinger G. The mesoneocortical dopamine neuron system // Neurology. – 1990; 40: 1660–2.
  22. Kopelman M. The cholinergic neurotransmitter system in human memory and dementia: a review // Quart. J. Exp. Psychol. – 1986; 38: 535–73.